Eclipse Diagnostics offering is now closed and is no longer accepting investments.
INVEST IN ECLIPSE DIAGNOSTICS TODAY!
Grower-friendly cannabis test
$179,058 Raised
REASONS TO INVEST
TEAM
Luka Fajs
President, CEO, Director
Prof. Robert S. Marks
Chief Scientist, Director
Tina Semolic
Marketing Advisor
TERMS
Eclipse Diagnostics
Overview
PRICE PER SHARE
$11
DEADLINE
Apr 30, 2020
VALUATION
$11.19M
AMOUNT RAISED
$179,058
Breakdown
MIN INVESTMENT
$495
MAX INVESTMENT
$109,989
MIN NUMBER OF SHARES OFFERED
909
OFFERING TYPE
Equity
ASSET TYPE
SHARES OFFERED
Common Stock
MAX NUMBER OF SHARES OFFERED
33,020
Maximum Number of Shares Offered subject to adjustment for bonus shares
Company | : | Eclipse Diagnostics Inc. |
Corporate Address | : | 750 N. San Vicente Blvd, Los Angeles, CA 90069 |
Offering Minimum | : | $9,999.00 |
Offering Maximum | : | $363,220.00 |
Minimum Investment Amount(per investor) | : | $495.00 |
Terms
Offering Type | : | Equity |
Security Name | : | Common Stock |
Minimum Number of Shares Offered | : | 909 |
Maximum Number of Shares Offered* | : | 33,020 |
Price per Share | : | $11.00 |
Pre-Money Valuation | : | $11,189,805.00 |
*Maximum subject to adjustment for bonus shares. See 10% Bonus below
Perks*
All investors
Regular updates on our technology progress
$5,000+
Exclusive content and regular company updates
Your place on the Technology Ambassadors Page of the website
1 Canabinox test kit
$10,000+
Exclusive content and regular company updates
Your place on the Technology Ambassadors Page of the website
2 Canabinox test kits
Invitation to our annual company VIP events
$50,000+
Exclusive content and regular company updates
Your place on the Technology Ambassadors Page of the website
4 Canabinox test kits
Once-a-year conference call with the CEO and founders
*All perks occur only after the offering is completed and if the products are available in the market
The 10% Bonus for StartEngine Shareholders
Eclipse Diagnostics Inc. will offer 10% additional bonus shares for all investments that are committed, within 24 hours of this offering going live, by StartEngine Crowdfunding Inc. shareholders who invested over $1,000 in the StartEngine Reg A offering which closed earlier this year.
StartEngine shareholders who invested $1,000 or more in that StartEngine Reg A offering will receive a 10% bonus on this offering within a 24-hour window of this offering’s launch date. This means you will receive a bonus for any shares you purchase. For example, if you buy 10 shares of Common Stock at $11 / share, you will receive 11 Common Stock shares, meaning you'll own 11 shares for $110. Fractional shares will not be distributed and share bonuses will be determined by rounding down to the nearest whole share.
This 10% bonus is only valid for one year from the time StartEngine Crowdfunding Inc. investors received their countersigned StartEngine Crowdfunding Inc. subscription agreement.
Irregular Use of Proceeds
The Company might incur Irregular Use of Proceeds that may include but are not limited to the following over $10,000: Any expense labeled “Administrative Expenses” not strictly for administrative purposes; Any expense labeled “Travel and Entertainment”; Inter company debt or back payments; Salary payments made to one’s self, a friend or relative; Vendor payments
ALL UPDATES
05.01.20
Notice to Investors
We will be unable to meet our April 29, 2020, annual report filing requirements for securities sold pursuant to Regulation CF as a result of administrative delays caused by shutdowns due to the COVID pandemic. As such, we intend to rely on the temporary relief being provided by the Securities and Exchange Commission. We will continue to use our best efforts to comply with our ongoing reporting obligations.
Thank you for your continued support.
Eclipse Diagnostics Team
04.28.20
Campaign Ending Soon. Last chance to invest.
Dear Investors,
Our campaign is ending tomorrow, April 29, 2020 at 11:59pm, so this is your last chance to invest in our Company and be part of our mission to provide easy, rapid and accurate testing for for medical and non-medical applications. We would like to thank all our investors so far and hope to be back soon.
Eclipse Diagnostics team
04.06.20
Notice of Funds Disbursement
[The following is an automated notice from the StartEngine team].
Hello!
As you might know, Eclipse Diagnostics has exceeded its minimum funding goal. When a company reaches its minimum on StartEngine, it's about to begin withdrawing funds. If you invested in Eclipse Diagnostics be on the lookout for an email that describes more about the disbursement process.
This campaign will continue to accept investments until its indicated closing date.
Thanks for funding the future.
-StartEngine
03.19.20
Eclipse Diagnostics March Update
Dear Investors,
We have some great updates on our research and development progress!
Laboratory Validations
We have been busy optimizing the performance and improving the design of our Eclipse THC/CBD reader. In the past months, we have continued to optimize both our hardware as well as software algorithms to enable a wider range of detection capabilities. We have made great progress in increasing the accuracy of our device from the initial 12% variability to the current 2% variability (THC(A)) measurements! We have performed our testing primarily on samples that had THCA levels between 3% and 30% and very low CBD levels, therefore we are now expanding our validation efforts to include all relevant THC(A) and CBD(A) combinations.
One of the key lessons learned during this process was that there is a large variability between laboratory data (that we rely on for the calibration) from different labs - inter-lab variability. The inter-lab variability can even range up to 50%! Therefore our main efforts were focused on identifying and partnering with reputable and reliable laboratories in the U.S. We anticipate that we will start our final round of laboratory validations in the coming weeks. This is, of course, dependent on the restrictions in place due to the Covid-19 outbreak.
A specific effort will be to validate the device for the differentiation of hemp vs. non-hemp to enable growers peace of mind during cultivation (crops that go above the legal cut-off of 0.3% THC get destroyed) and to provide law enforcement a tool to rapidly differentiate the same and prevent unnecessary shipment delays and damage to products.
Updated reader design
We have also been working on finalizing the design of the reader for mass production. This means that we had to redesign the case from a 3D-printable design to a design suitable for injection molding. We have completed this and improved the usability of the device by adding a hinge that now holds the reader cap in place and enables a more care-free operation. We have also identified suitable subcontractors for the manufacturing of the molds, as well as other components of the reader.
Updated branding
We designed a new logo and would like to hear your opinion! The goal of Eclipse Diagnostics is to provide a wide range of diagnostic products, from medical and non-medical applications and we want our branding to reflect that. We are also redesigning the website that will be available soon (we'll let you know when it's live).
Government grants
We submitted a DoD SBIR grant proposal with regard to the call topic "Diagnostic Platform for Rapid Identification of Pathogens in Infected Wounds that is Useable in a Battlefield Environment". We will be submitting more applications for government funding in the coming months, based on the applicability of the grant calls.
What's left to do
- The key activity is the final laboratory validation of the Eclipse reader system. With more data, we will be able to provide final performance specifications and test a wide range of samples.
- Finalize packaging design
- Injection molding of the case units
- Final assembly of the readers
We have received great interest from customers in the US, Europe, and Asia and believe that we can start fulfilling orders within weeks of completing the above tasks.
Impact of Covid-19
In light of the ongoing outbreak of Covid-19, we continue our research and development, we are enforcing social distancing and promote work from home as much as possible. The components of the Eclipse reader are readily available and we have not seen a significant impact on our supply chain. We anticipate that the Covid-19 will increase the demand for home/field testing solutions as access to laboratory testing could be limited.
Eclipse Diagnostics
03.17.20
Notice of Funds Disbursement
[The following is an automated notice from the StartEngine team].
Hello!
As you might know, Eclipse Diagnostics has exceeded its minimum funding goal. When a company reaches its minimum on StartEngine, it's about to begin withdrawing funds. If you invested in Eclipse Diagnostics be on the lookout for an email that describes more about the disbursement process.
This campaign will continue to accept investments until its indicated closing date.
Thanks for funding the future.
-StartEngine
03.09.20
Notice of Material Change in Offering
[The following is an automated notice from the StartEngine team].
Hello! Recently, a change was made to the Eclipse Diagnostics offering. Here's an excerpt describing the specifics of the change:
Extended length of campaign.
When live offerings undergo changes like these on StartEngine, the SEC requires that certain investments be reconfirmed. If your investment requires reconfirmation, you will be contacted by StartEngine via email with further instructions.
02.03.20
Notice of Funds Disbursement
[The following is an automated notice from the StartEngine team].
Hello!
As you might know, Eclipse Diagnostics has exceeded its minimum funding goal. When a company reaches its minimum on StartEngine, it's about to begin withdrawing funds. If you invested in Eclipse Diagnostics be on the lookout for an email that describes more about the disbursement process.
This campaign will continue to accept investments until its indicated closing date.
Thanks for funding the future.
-StartEngine
01.16.20
Notice of Funds Disbursement
[The following is an automated notice from the StartEngine team].
Hello!
As you might know, Eclipse Diagnostics has exceeded its minimum funding goal. When a company reaches its minimum on StartEngine, it's about to begin withdrawing funds. If you invested in Eclipse Diagnostics be on the lookout for an email that describes more about the disbursement process.
This campaign will continue to accept investments until its indicated closing date.
Thanks for funding the future.
-StartEngine
01.07.20
Notice of Material Change in Offering
[The following is an automated notice from the StartEngine team].
Hello! Recently, a change was made to the Eclipse Diagnostics offering. Here's an excerpt describing the specifics of the change:
Extended length of campaign.
When live offerings undergo changes like these on StartEngine, the SEC requires that certain investments be reconfirmed. If your investment requires reconfirmation, you will be contacted by StartEngine via email with further instructions.
12.19.19
Notice of Funds Disbursement
[The following is an automated notice from the StartEngine team].
Hello!
As you might know, Eclipse Diagnostics has exceeded its minimum funding goal. When a company reaches its minimum on StartEngine, it's about to begin withdrawing funds. If you invested in Eclipse Diagnostics be on the lookout for an email that describes more about the disbursement process.
This campaign will continue to accept investments until its indicated closing date.
Thanks for funding the future.
-StartEngine
JOIN THE DISCUSSION
0/2500
HOW INVESTING WORKS
Cancel anytime before 48 hours before a rolling close or the offering end date.
WHY STARTENGINE?
REWARDS
We want you to succeed and get the most out of your money by offering rewards and memberships!
SECURE
Your info is your info. We take pride in keeping it that way!
DIVERSE INVESTMENTS
Invest in over 200 start-ups and collectibles!
With Regulation A+, a non-accredited investor can only invest a maximum of 10% of their annual income or 10% of their net worth per year, whichever is greater. There are no restrictions for accredited investors.
With Regulation Crowdfunding, non-accredited investors with an annual income or net worth less than $124,000, are limited to invest a maximum of 5% of the greater of those two amounts. For those with an annual income and net worth greater than $124,000, he/she is limited to investing 10% of the greater of the two amounts.
At the close of an offering, all investors whose funds have “cleared” by this time will be included in the disbursement. At this time, each investor will receive an email from StartEngine with their Countersigned Subscription Agreement, which will serve as their proof of purchase moving forward.
Please keep in mind that a company can conduct a series of “closes” or withdrawals of funds throughout the duration of the campaign. If you are included in that withdrawal period, you will be emailed your countersigned subscription agreement and proof of purchase immediately following that withdrawal.
StartEngine assists companies in raising capital, and once the offering is closed, we are no longer involved with whether the company chooses to list shares on a secondary market, or what occurs thereafter. Therefore, StartEngine has no control or insight into your investment after the close of the live offering. In addition, we are not permitted to provide financial advice. You may want to contact a financial professional to discuss possible investment outcomes.
For Regulation Crowdfunding, investors are able to cancel their investment at any point throughout the campaign up until 48 hours before the closing of the offering. Note: If the company does a rolling close, they will post an update to their current investors, giving them the opportunity to cancel during this timeframe. If you do not cancel within this 5-day timeframe, your funds will be invested in the company, and you will no longer be able to cancel the investment. If your funds show as ‘Invested’ on your account dashboard, your investment can no longer be canceled.
For Regulation A+, StartEngine allows for a four-hour cancelation period. Once the four-hour window has passed, it is up to each company to set their own cancelation policy. You may find the company’s cancelation policy in the company’s offering circular.
Once your investment is canceled, there is a 10-day clearing period (from the date your investment was submitted). After your funds have cleared the bank, you will receive your refund within 10 business days.
Refunds that are made through ACH payments can take up to 10 business days to clear. Unfortunately, we are at the mercy of the bank, but we will do everything we can to get you your refund as soon as possible. However, every investment needs to go through the clearing process in order to get sent back to the account associated with the investment.
Both Title III (Regulation Crowdfunding) and Title IV (Reg A+) help entrepreneurs crowdfund capital investments from unaccredited and accredited investors. The differences between these regulations are related to the investor limitations, the differing amounts of money companies are permitted to raise, and differing disclosure and filing requirements. To learn more about Regulation Crowdfunding, click here, and for Regulation A+, click here.
